ATE507209T1 - Referenzstandard zur charakterisierung von rosuvastatin - Google Patents

Referenzstandard zur charakterisierung von rosuvastatin

Info

Publication number
ATE507209T1
ATE507209T1 AT04812772T AT04812772T ATE507209T1 AT E507209 T1 ATE507209 T1 AT E507209T1 AT 04812772 T AT04812772 T AT 04812772T AT 04812772 T AT04812772 T AT 04812772T AT E507209 T1 ATE507209 T1 AT E507209T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
characterization
reference standard
standard
analysis
Prior art date
Application number
AT04812772T
Other languages
English (en)
Inventor
Nina Finkelstein
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE507209T1 publication Critical patent/ATE507209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04812772T 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin ATE507209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52644903P 2003-12-02 2003-12-02
PCT/US2004/040329 WO2005056534A1 (en) 2003-12-02 2004-12-02 Reference standard for characterization of rosuvastatin

Publications (1)

Publication Number Publication Date
ATE507209T1 true ATE507209T1 (de) 2011-05-15

Family

ID=34676616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812772T ATE507209T1 (de) 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin

Country Status (13)

Country Link
US (6) US7244844B2 (de)
EP (1) EP1689723B1 (de)
JP (1) JP4733047B2 (de)
KR (1) KR100887264B1 (de)
CN (1) CN1894221B (de)
AT (1) ATE507209T1 (de)
CA (1) CA2546894C (de)
DE (1) DE602004032465D1 (de)
ES (1) ES2364143T3 (de)
IL (1) IL175511A (de)
PT (1) PT1689723E (de)
TW (1) TWI351958B (de)
WO (1) WO2005056534A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1689723B1 (de) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
TWI353981B (en) * 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
CA2630704C (en) * 2005-12-20 2014-08-19 Lek Pharmaceuticals D.D. Pharmaceutical composition
JP5330225B2 (ja) * 2007-03-13 2013-10-30 テバ ファーマシューティカル インダストリーズ リミティド トリオール型ロスバスタチン
EP2189456A1 (de) * 2008-11-14 2010-05-26 LEK Pharmaceuticals d.d. Neue Omeprazol-Verbindungen
CA2748491C (en) 2008-12-30 2019-08-06 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CN103454352B (zh) * 2013-07-30 2015-07-15 广东先强药业有限公司 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) * 2014-02-11 2014-05-07 润泽制药(苏州)有限公司 瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) * 2018-07-23 2020-06-02 唯智医药科技（北京）有限公司 一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37314A (en) * 1863-01-06 Improved composition for lemonade
US633198A (en) * 1899-02-08 1899-09-19 Wilhelm Magnus Hoekerstedt Automatic-lighting torch.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
WO1992022560A1 (fr) 1991-06-19 1992-12-23 Shionogi Seiyaku Kabushiki Kaisha Intermediaire optiquement actif et production de celui-ci
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1585736A2 (de) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Verfahren zur herstellung von rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US7566782B2 (en) 2002-12-10 2009-07-28 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
AU2003269478A1 (en) 2003-08-27 2005-03-16 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
EP1678148A1 (de) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Verfahren zur herstellung von amorphen rosuvastatin-calcium
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (de) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Referenzstandard zur charakterisierung von rosuvastatin
US20080234302A1 (en) 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
JP2008528542A (ja) 2005-01-31 2008-07-31 チバ ホールディング インコーポレーテッド ロスバスタチンカルシウム塩の結晶形
WO2006100689A1 (en) 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
US20080161560A1 (en) 2005-04-04 2008-07-03 Pandurang Balwant Deshpande Process for Preparation of Calcium Salt of Rosuvastatin
WO2006136407A1 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136408A2 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
CA2546894A1 (en) 2005-06-23
US7692008B2 (en) 2010-04-06
JP2007512354A (ja) 2007-05-17
DE602004032465D1 (de) 2011-06-09
KR100887264B1 (ko) 2009-03-06
IL175511A0 (en) 2006-09-05
TW200522959A (en) 2005-07-16
KR20060098396A (ko) 2006-09-18
TWI351958B (en) 2011-11-11
WO2005056534A1 (en) 2005-06-23
US7244844B2 (en) 2007-07-17
US20090188305A1 (en) 2009-07-30
CN1894221B (zh) 2012-08-08
US7692009B2 (en) 2010-04-06
EP1689723B1 (de) 2011-04-27
US8487097B2 (en) 2013-07-16
US20070255059A1 (en) 2007-11-01
JP4733047B2 (ja) 2011-07-27
CN1894221A (zh) 2007-01-10
PT1689723E (pt) 2011-07-06
US20070249831A1 (en) 2007-10-25
IL175511A (en) 2011-11-30
US7692010B2 (en) 2010-04-06
US7741482B2 (en) 2010-06-22
EP1689723A1 (de) 2006-08-16
ES2364143T3 (es) 2011-08-25
CA2546894C (en) 2009-09-08
US20070244321A1 (en) 2007-10-18
US20050187234A1 (en) 2005-08-25
US20070249830A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE507209T1 (de) Referenzstandard zur charakterisierung von rosuvastatin
ATE307618T1 (de) Vorrichtung zur abgabe von flüchtigen stoffen
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DE60007095D1 (de) Calanolide zur hemmung von btk
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE60301922D1 (de) Vorrichtung zur Entnahme von Objekten
DE50207852D1 (de) Verwendung von fettalkoholethoxylaten als penetrationsförderer
DE602004025507D1 (de) Vanillin-polymere zwecks verwendung zur verdunklung der haut
DE60318831D1 (de) System zur abgabe von anästhetika
EA200500064A1 (ru) Многофункциональные маркеры продуктов и способы их получения и применения
DE60223780D1 (de) Verfahren zur Entfernung von Kunstrasenböden, entsprechende Verwendung und Produkt
UY27192A1 (es) Inhibidores de peptido-deformilasa
ECSP045466A (es) Inhibidores de la peptido-desformilasa
DE60333196D1 (de) Atemerfrischer und mundpflegeprodukt unter verwendung von kardamom l
DE60234250D1 (de) Vorrichtung zur Zell- bzw. Gewebezüchtung
EP1642969A4 (de) Fluoreszenzprotein und pigmentprotein
AU2003223634A1 (en) Peptide deformylase inhibitors
BR0316544A (pt) Compostos calcilìticos
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
DE602004002532D1 (de) Vorrichtung zur Herstellung von Broschüren
DE60207833D1 (de) Peptiddeformylase-hemmer
AU2003304490A1 (en) Peptide deformylase inhibitors
IS7441A (is) Peptíðdeformýlasatálmar
AU2003209735A1 (en) Filament-recruiting fluorescent proteins for the analysis and identification of protein-protein-interactions
DE60232650D1 (de) Peptiddeformylaseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties